Bolt Biotherapeutics, Inc.
Clinical trials sponsored by Bolt Biotherapeutics, Inc., explained in plain language.
-
First human test of experimental cancer drug halted early
Disease control TerminatedThis was an early-stage study to test the safety and find the right dose of a new drug called BDC-3042, both alone and combined with an existing immunotherapy (cemiplimab). It involved 17 adults with advanced cancers who had run out of standard treatment options. The main goals w…
Phase: PHASE1 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Apr 04, 2026 06:35 UTC
-
New drug combo tested for Tough-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new drug called BDC-1001, both by itself and combined with an existing immunotherapy drug (nivolumab), for people with advanced cancers that have a specific marker called HER2. The main goals were to find safe doses and see if the treatments could …
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Trial for tough breast cancer cases halted early
Disease control TerminatedThis study tested an experimental drug called BDC-1001, both alone and combined with an existing drug (pertuzumab), for people with advanced HER2-positive breast cancer that had worsened after standard treatments. The goal was to see if the treatment could shrink tumors and was s…
Phase: PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC